There is growing criticism of us health funding agreements with african countries, with some characterizing these deals as unfair. These agreements reportedly involve african countries receiving funding in exchange for access to patient data, sparking concerns about the potential costs and implications. The impact of these deals on access to essential medications in african countries is also being questioned.